MinKe He, MD; QiJiong Li, MD; RuHai Zou, MD; et al.
free access
JAMA Oncol. 2019;5(7):953-960. doi:10.1001/jamaoncol.2019.0250
This randomized clinical trial examines whether combined sorafenib and hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin is associated with improved survival of patients with hepatocellular carcinoma and portal vein invasion compared with sorafenib alone, the current standard systemic treatment.
Erin D. Kennedy, MD, PhD; Marko Simunovic, MD, MPH; Kartik Jhaveri, MD; et al.
free access
JAMA Oncol. 2019;5(7):961-966. doi:10.1001/jamaoncol.2019.0186
This nonrandomized phase 2 clinical trial evaluates the safety and feasibility of using magnetic resonance imaging criteria to select patients with 鈥済ood prognosis鈥� rectal tumors for primary surgery.
-
Editorial
Reducing the Morbidity of Rectal Cancer Treatment
Philip B. Paty, MD; Andrea Cercek, MD; Christopher H. Crane, MD
JAMA Oncol
Justin C. Brown, PhD; Bette J. Caan, DrPH; Carla M. Prado, PhD; et al.
free access
JAMA Oncol. 2019;5(7):967-972. doi:10.1001/jamaoncol.2019.0695
This population-based cohort study assesses 5 measures of body composition to determine which measures are associated with major adverse cardiovascular events in patients with colorectal cancer.
Robert T. Dess, MD; Holly E. Hartman, MS; Brandon A. Mahal, MD; et al.
free access
JAMA Oncol. 2019;5(7):975-983. doi:10.1001/jamaoncol.2019.0826
This multiple-cohort study quantifies the association of black race with long-term survival outcomes after controlling for known prognostic variables and access to care among men with prostate cancer.
-
Invited Commentary
Racial Inequality in Prostate Cancer Outcomes鈥擲ocioeconomics, Not Biology
Channing J. Paller, MD; Lin Wang, MSc, MMed; Otis W. Brawley, MD
JAMA Oncol
Carole Fakhry, MD; Amanda L. Blackford, ScM; Geoff Neuner, MD; et al.
free access
JAMA Oncol. 2019;5(7):985-992. doi:10.1001/jamaoncol.2019.0439
This cohort study investigates whether the prevalence of human papillomavirus (HPV) DNA after completion of primary cancer therapy is associated with recurrence-free survival and overall survival among patients with HPV-positive head and neck squamous cell carcinoma.
Thomas B. Karasic, MD; Mark H. O鈥橦ara, MD; Arturo Loaiza-Bonilla, MD; et al.
free access
JAMA Oncol. 2019;5(7):993-998. doi:10.1001/jamaoncol.2019.0684
This phase 2 randomized clinical trial examines whether hydroxychloroquine sulfate improves overall survival at 1 year in combination with gemcitabine hydrochloride and nab-paclitaxel among previously untreated adults with metastatic pancreatic cancer.
Melissa L. Johnson, MD; Fadi Braiteh, MD; Juneko E. Grilley-Olson, MD; et al.
open access
JAMA Oncol. 2019;5(7):999-1007. doi:10.1001/jamaoncol.2019.0836
This phase 1 dose-escalation trial compares the safety, tolerability, and pharmacokinetics of PF-06801591, a monoclonal antibody, administered subcutaneously vs intravenously in patients with advanced or metastatic solid tumors.
Yucai Wang, MD, PhD; Shouhao Zhou, PhD; Fang Yang, MD, PhD; et al.
free access
JAMA Oncol. 2019;5(7):1008-1019. doi:10.1001/jamaoncol.2019.0393
This systematic review and meta-analysis describes the various adverse events associated with PD-1 and PD-L1 inhibitor drugs reported in clinical trials indexed in PubMed, Web of Science, Embase, and Scopus.
Janet E. Murphy, MD, MPH; Jennifer Y. Wo, MD; David P. Ryan, MD; et al.
free access
JAMA Oncol. 2019;5(7):1020-1027. doi:10.1001/jamaoncol.2019.0892
This single-arm phase 2 clinical trial evaluates the margin-negative resection rate in locally advanced pancreatic cancer after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) and losartan therapy and individualized chemoradiotherapy.
Vikram Jairam, MD; Victor Lee, BS; Henry S. Park, MD, MPH; et al.
free access
JAMA Oncol. 2019;5(7):1028-1035. doi:10.1001/jamaoncol.2019.0086
This cohort study of 1.5 million ED visits examines rates, costs, and outcomes of emergency department visits by patients with cancer who are undergoing chemotherapy or radiotherapy.
Constance D. Lehman, MD, PhD; Constantine Gatsonis, PhD; Justin Romanoff, MA; et al.
free access
JAMA Oncol. 2019;5(7):1036-1042. doi:10.1001/jamaoncol.2018.6269
This nonrandomized clinical trial of women with ductal carcinoma in situ examines reasons for conversion to mastectomy after magnetic resonance imaging and adherence to radiotherapy use guided by the 12-gene ductal carcinoma in situ score.